Enliven Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our corporate headquarters are currently located in Boulder, Colorado, where we sublease approximately 18,170 square feet of office and laboratory space pursuant to a sublease agreement that expires on December 30, 2024. We believe that our facility will be adequate for our near-term needs. However, we are actively assessing alternative spaces and we believe that alternative suitable space will be available on commercially reasonable terms.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.